WordNet
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
- how long something has existed; "it was replaced because of its age"
- a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
- begin to seem older; get older; "The death of his wife caused him to age fast"
- make older; "The death of his child aged him tremendously"
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
- 〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
- Huang BT1, Zeng QC2, Zhao WH3, Li BS4, Chen RL5.
- Leukemia research.Leuk Res.2014 Oct;38(10):1177-83. doi: 10.1016/j.leukres.2014.06.019. Epub 2014 Jul 15.
- OBJECTIVE: This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN α-2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation.METHOD: A total of 123 ET patients received IFNα-2b therapy
- PMID 25069759
- Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
- Yawn BP1, Buchanan GR2, Afenyi-Annan AN3, Ballas SK4, Hassell KL5, James AH6, Jordan L7, Lanzkron SM8, Lottenberg R9, Savage WJ10, Tanabe PJ11, Ware RE12, Murad MH13, Goldsmith JC14, Ortiz E15, Fulwood R16, Horton A17, John-Sowah J18.
- JAMA.JAMA.2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517.
- IMPORTANCE: Sickle cell disease (SCD) is a life-threatening genetic disorder affecting nearly 100,000 individuals in the United States and is associated with many acute and chronic complications requiring immediate medical attention. Two disease-modifying therapies, hydroxyurea and long-term blood t
- PMID 25203083
- The challenge of creating an evidence-based guideline for sickle cell disease.
- DeBaun MR.
- JAMA.JAMA.2014 Sep 10;312(10):1004-5. doi: 10.1001/jama.2014.11103.
- PMID 25203081
Japanese Journal
- New isocratic high-performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea in plasma with ultraviolet detection
- Journal of chromatography. B, Biomedical sciences and applications 709(1), 119-126, 1998-05-08
- NAID 10024528393
Related Links
- Sickle cell anemia and antisickling agents then and now. Mehanna AS. Department of Pharmaceutical Sciences, School of Pharmacy, Massachusetts College of Pharmacy and Health sciences, 179 Longwood Avenue, Boston, MA 02115, ...
- Cetiedil has been reported to relieve painful crises in sickle cell anemia and to have antisickling properties in vitro. The drug alters neither oxygen affinity nor the solubility of deoxyhemoglobin S. Because the viscosity of the erythrocyte interior ...
Related Pictures
★リンクテーブル★
[★]
- 英
- antisickling agent
- 関
- 鎌状赤血球貧血治療薬
[★]
- 英
- antisickling agent
- 関
- 抗鎌状化薬
[★]
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、~剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle
[★]
- 関
- aged、ageing、aging、year old